Skip to main content

Health & Fitness The human genome project, 10 years in: Did they oversell the revolution?

It was billed as one of the pivotal moments in the history of medicine. A decade ago this month, researchers published their long-awaited results of deciphering the human genome – providing the genetic blueprint of our species.

Many experts claimed the new knowledge would spark a genetic revolution. They said doctors would soon be able to accurately predict who among their patients was most at risk of developing certain diseases. And patients, in turn, would be able to take corrective action – either by adjusting their behaviour or using new gene-based therapies.

But a retrospective paper, which will be published Friday in the journal Science, points out the "revolution" has not lived up to expectations – at least not yet.

Story continues below advertisement

The article, "Deflating the Genomic Bubble," was penned by geneticist James Evans of the University of North Carolina, bioethicist Eric Meslin of Indiana University, psychologist Theresa Marteau of King's College London and law professor Timothy Caulfield of the University of Alberta.

"The predictive value of so much of this genetic risk information is really quite low," Prof. Caulfield said in an interview. "It has proven to be far more complex and far more nuanced than imagined."

Or, simply put, just because you are born with a certain group of genes, it doesn't mean you are going to get a particular disease or steer clear of it either.

Dr. Evans said it was naive to assume that genes would provide a crystal-ball view into a person's future, "because common diseases have many causes and genetics is only one factor."

He added that it was equally naive to assume that people would adjust their behaviour – like eating a healthier diet or quitting smoking – when genetic tests implied they were at risk of an early death if they didn't mend their ways.

Another disappointment is that there has not been the anticipated flood of new therapies spilling forth from the $3-billion (U.S.) that is spent annually on genetic research worldwide.

Dr. Evans and his co-authors still have high hopes for the field. "We don't want to trash genomics." In fact, they say, there have been a few major discoveries that have profoundly affected the lives of some individuals. Women born with mutations in the so-called BRCA1 and BRCA2 genes face an 85-per-cent lifetime risk of getting breast cancer. And genetic tests can now help determine who will benefit most from certain cancer therapies.

Story continues below advertisement

But, he said, those specific examples are the exceptions rather than the rule. For the most part, the true promise of genomics lies in its ability to lay bare the mechanisms of disease. "That will ultimately have great payoff in human health. It is just going to take a long time," Dr. Evan said.

Meanwhile, inflated claims of immediate genomic benefits could threaten the long-term credibility of the field. To make matters worse, an over-emphasis on genes "may also distract our gaze from other promising approaches to preventing disease and improving health," the authors warn in the article.

"Our argument is that we are not doing the field of genetics any favours if we unrealistically hype its promise," said Dr. Evans. "Indeed, by doing so, we risk a backlash that will set the field back."

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter